It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.

Latest Updates: November 2023

Latest Publications:

As of March 25, 2023, a total of 2,9341 patients received siponimod in clinical trials including open-label extensions and, as of March 25, 2023, the estimated postmarketing exposure was 31,187 patients years.**

Home page figure_v1
**Postmarketing exposure is estimated from the global sales data
Border image
COVID-19, corona virus disease-19; HCP, health-care professional
1. Data on File, cutoff date 25-March-2023, Novartis Pharma AG.
2. Data on File, PSUR, cutoff date 25-March-2023, Novartis Pharma AG.
▼ In the European Union / European Economic Area and certain other countries, this medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. Click on the button above to access to the siponimod product information or to report adverse reactions.
* Indication varies in different countries. Current website is a global information resource. Local Prescribing Information/ Summary of Product Characteristics approved by individual country’s regulatory authority is the primary source of information for the indication of siponimod in the individual country.

The Pregnancy outcome Intensive Monitoring (PRIM) program is based on enhanced pharmacovigilance of the Novartis spontaneous reporting system. PRIM is an adverse event outcomes intensive monitoring program to collect information (targeted follow-up checklists) about pregnancy in patients exposed to siponimod immediately before or during pregnancy and infant outcomes 12 months after delivery.